» Articles » PMID: 32433604

High Placental Inositol Content Associated with Suppressed Pro-adipogenic Effects of Maternal Glycaemia in Offspring: the GUSTO Cohort

Abstract

Background/objectives: Maternal glycaemia promotes fetal adiposity. Inositol, an insulin sensitizer, has been trialled for gestational diabetes prevention. The placenta has been implicated in how maternal hyperglycaemia generates fetal pathophysiology, but no studies have examined whether placental inositol biology is altered with maternal hyperglycaemia, nor whether such alterations impact fetal physiology. We aimed to investigate whether the effects of maternal glycaemia on offspring birthweight and adiposity at birth differed across placental inositol levels.

Methods: Using longitudinal data from the Growing Up in Singapore Towards healthy Outcomes cohort, maternal fasting glucose (FPG) and 2-hour plasma glucose (2hPG) were obtained in pregnant women by a 75-g oral glucose tolerance test around 26 weeks' gestation. Relative placental inositol was quantified by liquid chromatography-mass spectrometry. Primary outcomes were birthweight (n = 884) and abdominal adipose tissue (AAT) volumes measured by neonatal MRI scanning in a subset (n = 262) of term singleton pregnancies. Multiple linear regression analyses were performed.

Results: Placental inositol was lower in those with higher 2hPG, no exposure to tobacco smoke antenatally, with vaginal delivery and shorter gestation. Positive associations of FPG with birthweight (adjusted β [95% CI] 164.8 g [109.1, 220.5]) and AAT (17.3 ml [11.9, 22.6] per mmol glucose) were observed, with significant interactions between inositol tertiles and FPG in relation to these outcomes (p < 0.05). Stratification by inositol tertiles showed that each mmol/L increase in FPG was associated with increased birthweight and AAT volume among cases within the lowest (birthweight = 174.2 g [81.2, 267.2], AAT = 21.0 ml [13.1, 28.8]) and middle inositol tertiles (birthweight = 202.0 g [103.8, 300.1], AAT = 19.7 ml [9.7, 29.7]). However, no significant association was found among cases within the highest tertile (birthweight = 81.0 g [-21.2, 183.2], AAT = 0.8 ml [-8.4, 10.0]).

Conclusions: High placental inositol may protect the fetus from the pro-adipogenic effects of maternal glycaemia. Studies are warranted to investigate whether prenatal inositol supplementation can increase placental inositol and reduce fetal adiposity.

Citing Articles

A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System.

Beresniak A, Russo M, Forte G, Lagana A, Oliva M, Aragona C Sci Rep. 2023; 13(1):17789.

PMID: 37853019 PMC: 10584971. DOI: 10.1038/s41598-023-44055-0.


Myo-inositol alters the effects of glucose, leptin and insulin on placental palmitic acid and oleic acid metabolism.

Watkins O, Pillai R, Selvam P, Yong H, Cracknell-Hazra V, Sharma N J Physiol. 2023; 601(18):4151-4169.

PMID: 37602663 PMC: 10952252. DOI: 10.1113/JP285036.


Myo-Inositol Moderates Glucose-Induced Effects on Human Placental C-Arachidonic Acid Metabolism.

Watkins O, Cracknell-Hazra V, Pillai R, Selvam P, Yong H, Sharma N Nutrients. 2022; 14(19).

PMID: 36235641 PMC: 9572372. DOI: 10.3390/nu14193988.


Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental C-DHA-metabolism, altering their relationships with birthweight.

Watkins O, Selvam P, Pillai R, Cracknell-Hazra V, Yong H, Sharma N Sci Rep. 2022; 12(1):14895.

PMID: 36050341 PMC: 9437079. DOI: 10.1038/s41598-022-18309-2.


Developmental Effects of (Pre-)Gestational Diabetes on Offspring: Systematic Screening Using Omics Approaches.

Shashikadze B, Flenkenthaler F, Stockl J, Valla L, Renner S, Kemter E Genes (Basel). 2021; 12(12).

PMID: 34946940 PMC: 8701487. DOI: 10.3390/genes12121991.


References
1.
Toh N, Inoue T, Tanaka H, Kimoto E . Polyol accumulation in human placenta and umbilical cord. Biol Res Pregnancy Perinatol. 1987; 8(1 1ST Half):13-5. View